Kornimate/medical-research-clean huggingface dataset:
assessment of serum concentration of interleukin-17 and osteoprotegerin in response to surgical trauma induced by management of mandibular fractures via intraoral versus extraoral approaches: prospective cohort study

Conditions: Mandibular Fractures

Summary: assessment of serum concentration of interleukin-17 and osteoprotegerin in response to surgical trauma induced by management of mandibular fractures via intraoral versus extraoral approaches: prospective cohort study


Eligibility criteria:
inclusion criteria: * single mandibular fracture. * orif is done by two plates fixation with titanium plates and screws. * age (18-50 years). * recent fracture (less than 2 weeks). exclusion criteria: * pathological fractures. * medical compromised patient. * presence of concomitant injuries. * patients receive radiotherapy. * patients receive blood transfusion.
evaluation of antiproliferative effects of arimidex in ductal lavage fluid in patients with breast cancer

Conditions: Breast Cancer

Summary: the goal of this study is to evaluate antiproliferative effects of arimidex in ductal lavage fluids of breast cancer patients. breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.


Eligibility criteria:
inclusion criteria: * patient must have a history of breast cancer. * patient must be scheduled to receive standard treatment with arimidex for adjuvant hormonal management. * patient must be willing to undergo a duct lavage. * patient must sign an informed consent. exclusion criteria: * none.

Keywords: cancer arimidex
low dose gnrha early luteal phase down regulation versus gnrha ultra-short protocol for poor ovarian response

Conditions: Subfertility, Female; Ovulation Disorder

Summary: the management of the poor responder patients is very difficult. currently, there is no any standard treatment for poor responder patients. the study is designed to test a modified gnrha protocol for poor ovarian response, low dose gnrha early luteal phase down regulation, compare with gnrha ultra-short protocol. this is a randomized controlled trial.


Eligibility criteria:
inclusion criteria: * at least two of the following three features must be present: i. advanced maternal age (≥40 years) or any other risk factor for por (poor ovarian response); ii. a previous por (≤3 oocytes with a conventional stimulation protocol); iii. an abnormal ovarian reserve test (i.e. afc \<7 follicles or amh \<1.1 ng/ml). exclusion criteria: * contraindications for ivf/icsi * contraindications for pregnancy * primary ovarian insufficiency * afc \<3 * pgd/pgs
neocortical microarchitecture of executive function

Conditions: Parkinson Disease

Summary: this study is being done to the determine the ability and utility of using the neuropixels probes in the human brain. a neuropixels probe will be inserted into and removed from the brain of awake human patients who are undergoing awake deep brain stimulation (dbs) surgery.

this project aims to use neuropixels probes to record hundreds of neurons during awake human intracranial surgeries. using this probe, we will take advantage of access to a key area in the network involved in executive function, the middle frontal gyrus of the dorsal lateral pre frontal cortex (approximately the mid portion of dlpfc, part of brodmann area 9/46), to test emerging concepts that cognitive flexibility so crucial to human ef is encoded in neural population geometry and layer-specific interactions.

Eligibility criteria:
inclusion criteria: 1. diagnosis of parkinson's disease and refractory to medications requiring deep brain stimulation 2. aged 45-85 3. able to provide informed consent 4. normal neuropsychiatric evaluation that includes tests of executive function. 5. medically able to undergo deep brain stimulation surgery as evaluated by study neurosurgeon. 6. surgical plan includes an entry point that can safely be placed in the dorsal lateral pfc. 7. able to tolerate awake deep brain stimulation surgery with a plan for the case to be done awake. 8. able to tolerate 25 additional minutes of awake surgery. 9. able to participate and comply with tasks adequately, including instructions provided in english. exclusion criteria: 1. moderate, or severe cognitive impairment as determined by a licensed neuropsychologist during routine neuropsychological evaluation. 2. inability to tolerate awake surgery as determined by the treating neurologist and study neurosurgeon. 3. inability to safely access the dorsal lateral prefrontal cortex for an entry location. 4. cognitive impairment or executive function deficits as determined by neuropsychological testing 5. evidence of a clinically significant abnormality on preoperative imaging.
diastolic dysfunction in morbidly obese patients undergo bariatric surgery

Conditions: Diastolic Dysfunction; Morbid Obesity

Summary: morbidly obese patients are at risk for diastolic cardiac dysfunction, which can lead to adverse event, such as, diastolic heart failure postoperatively. preoperative screening by transthoracic echocardiogram is difficult due to anatomical challenge, therefore the prevalence of this problem may be underestimated. the investigator would like to perform transesophageal echocardiogram in this group of patients after anesthesia induction to demonstrate the true prevalence of this syndrome.

morbidly obese patients are at risk for both respiratory and cardiovascular abnormalities. many cardiac problems were previously reported including left ventricular hypertrophy, right and left ventricular systolic dysfunction etc. diastolic cardiac dysfunction can be found in normal left ventricular systolic function and can lead to diastolic heart failure postoperatively. preoperative screening by transthoracic echocardiogram is difficult due to anatomical challenge (thick chest wall, narrowing of inter-rib space), therefore the prevalence of this problem may be underestimated. transesophageal echocardiogram provides better cardiac view, but requires sedation during procedure. so, it is not practical for out-patient setting. the investigator would like to perform transesophageal echocardiogram in this group of patients after anesthesia induction to demonstrate the true prevalence of this syndrome.

Eligibility criteria:
inclusion criteria: * every patient scheduled for bariatric surgery in siriraj hospital exclusion criteria: * patient refusal * patient with contraindication for transesophageal echocardiogram such as preexisting esophageal disease, recent upper gastrointestinal bleeding, coagulopathy, etc. (according to american society of echocardiography guideline)

Keywords: diastolic dysfunction morbid obesity bariatric surgery
the effect of vaginal estrogen cream on subjective and objective symptoms of urodynamic stress incontinence

Conditions: Stress Urinary Incontinence

Summary: this is a randomized, double blinded placebo controlled trial over a period of 3 months. study subjects will be randomized into 2 groups: those receiving drug (1gm of estrogen vaginal cream \[evc\] at bed time 3 times a week), and those receiving placebo.

1. this will be a randomized, double blinded placebo controlled trial over a period of 3 months. study subjects will be randomized into 2 groups: those receiving drug (1gm of estrogen vaginal cream \[evc\] at bed time 3 times a week), and those receiving placebo. study subjects will be patients diagnosed with stress urinary incontinence by urodynamic evaluation. they will have filled out the iiq-7 and udi-6 validated questionnaires as is routine for all patients being evaluated for stress incontinence. after enrollment and informed consent, their initial screening will include a pap smear for vaginal maturation. 2. subjects will then be seen at 4, 8 and 12 weeks. at each visit, they will turn in their medication tubes and receive new study medication. they will also be screened for any adverse reaction to the study medication at each visit. 3. at the end of the study period, the subjects will fill out the same validated questionnaire as they did at the beginning of the study and they will also have their urethral pressure profile and pap smear repeated. 4. the urethral pressure profile is part of the standard complex urodynamic testing that all patients undergo for evaluation and diagnosis of urodynamic stress incontinence. urethral pressure profile is a technique used to provide information about the ability of the urethra to prevent leakage. the urethral pressure profile is a specific study, in which a special design catheter is pulled through the urethra at a slow, continuous rate. the resulting "bell shaped" curve illustrates the function of the urethra from the beginning of the bladder neck out through the meatus. 5. the placebo cream will be a pharmacologically inert formulation which will be packaged similarly to the active premarin cream and visually indistinguishable from the active drug to both the study subjects and researchers.

Eligibility criteria:
inclusion criteria: * english speaking * postmenopausal women (no menses for a minimum period of 1 year) * urodynamic stress urinary incontinence exclusion criteria: * history of breast or uterine cancer * history of venous thrombolic event * hormone replacement therapy within 3 months of study * sensitivity or allergy to premarin cream * current use of any medications for urge or stress incontinence * prior surgery for stress incontinence * overactive bladder or detrussor instability * active vaginal/ bladder infection (patients will be treated and have a negative test for cure in order to be enrolled in the study) * history of pelvic or vaginal radiation therapy

Keywords: urodynamic stress incontinence postmenopausal women
study of personalized sterile humidification device for mucositis in head and neck cancer patients

Conditions: Head and Neck Cancer

Summary: this is a single arm study of the use of a personalized sterile humidification device for 12 weeks for head and neck cancer patients undergoing radiation therapy to determine if the usage of this humidification system will result in a decrease in severity in head and neck related quality of life as measured by the mdasi hn subscale following radiation therapy as compared with historical experience. in addition, we are exploring correlative measures using crp, il-1, il-6, and tnf-alpha level measurements as these are directly related to mucositis and presumably related to quality of life as indicated by the patient.

the patients complete mdasi at baseline, 6 weeks, and 12 weeks. the mdasi is a validated instrument that measures symptom burden and we measure a subscale (hn) as our primary endpoint. the patients are asked to use a personal humidifier daily and complete a weekly diary showing compliance with the humidifier use.

Eligibility criteria:
inclusion criteria: * receiving a dose of radiation therapy greater than or equal to 6000 cgy to one third of the oral cavity. * receiving definitive or post-operative adjuvant radiotherapy. * receiving radiotherapy or chemoradiation. * of age greater than 18 years. * life expectancy greater than 6 months. * able to provide informed consent. * participation of patients on other clinical trial protocols permitted, if not prohibited by trial guidelines. exclusion criteria: * undergoing induction or neoadjuvant chemotherapy prior to radiotherapy. * treatment with amifostine or palifermin (keratinocyte growth factor) during radiotherapy. * high risk for poor compliance with radiotherapy, humidification, or follow-up as assessed by the investigator.

Keywords: quality of life
proteasis evaluation in copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the aim of this study was to evaluate kallikreins and its substrate, ccn, in copd patients. kallikreins are a subgroup of serine proteases, enzymes which are able to cleave peptide bonds in proteins. kallicrein profile is unkonwn in copd. the investigators will assess kallikrein 1 to 15 and ccn 1 to 6 in sputum of patients. three groups of patients will be included: healthy smoker subjects, stable copd patients and copd patients with acute exacerbation. kallicrein levels in sputum will be compared in these groups.


Eligibility criteria:
inclusion criteria for healthy subjects: * smoker with tobacco consumption of 20 pack/year * normal lung function tests exclusion criteria for healthy subjects: * diagnosis of lung disease during the study * asthma * lung cancer * pregnant and lactating women inclusion criteria for stable copd: * smoker with tobacco consumption of 20 pack/year * fev1/fvc\<70% on lung function tests * no hospitalisation for exacerbation during 3 months before inclusion exclusion criteria for stable copd: * asthma * lung cancer * pregnant and lactating women inclusion criteria for copd with exacerbation: * smoker with tobacco consumption of 20 pack/year * worsening of pulmonary symptoms * fev1/fvc\<70% on lung function tests could be obtain before or 3 months after exacerbation exclusion criteria for copd with exacerbation: * asthma * lung cancer * pregnant and lactating women
bad breath response to tongue scraper and rinses

Conditions: Halitosis

Summary: medical center personnel were screened organoleptically for bad breath by 2 investigators using rosenberg scale 0-5, and measurement of breath sample in portable gas chromatograph. with a threshold score of 2 or more, or 75parts per billion(ppb) hydrogen sulfide(h2s), subjects invited to enter clinical trial of the mechanical effect of daily tongue scraping with the adjunctive use of 0.12% chlorhexidine gluconate mouthwash or 0.1% stabilized chlorine dioxide mouthwash. subjects randomly assigned in double-blind trial for one week. the null hypothesis is there will be no difference between the two rinses as adjuncts to tongue scraping.

subjects in trial had oral and periodontal exam and scored the ramfjord teeth(#3, 9, 12, 19, 25, 28) for plaque index(pli), gingival index(gi), probing depth (pd), recession. a tongue coating index is scored and sample of coating on dorsum taken for culture of total viable count and percentage of black sulfide-producing colonies on anaerobe agar with lead acetate added. subjects given hygiene instruction and instruction on use of scraper, then rinse with 20ml assigned mouthwash 30sec. breath assessed by organoleptic means and mouth air sample concentration of hydrogen sulfide, methyl mercaptan in portable gas chromatograph at 0, 1, 2, and 4 hours. subjects use scraper and mouthwash twice daily for one week and return for final exam.

Eligibility criteria:
inclusion criteria: * adult with threshold score of 2 on organoleptic halitosis evaluation exclusion criteria: * taking another experimental drug, or antibiotic.
handheld infrared thermometer to evaluate cellulitis

Conditions: Cellulitis; Cellulitis of Arm; Cellulitis of Leg

Summary: it can be difficult to differentiate cellulitis from non-infectious mimics, like venous stasis. one way of determining the difference is feeling skin surface temperature. however, this is a subjective measure that is inherently unreliable. it might be possible to objectify this measurement by using a non-contact infrared thermometer at the bedside. the goal of this study is therefore to assess whether objective difference in skin surface temperature in an area of suspected cellulitis, relative to non-affected skin, has diagnostic utility. it will use the diagnosis of cellulitis by an infectious diseases physician as the gold standard and compare blinded temperature difference between affected and unaffected limbs to that standard. it is hypothesized that measurement of skin surface temperature by non-contact infrared thermometer will help differentiate cellulitis from many non-infectious conditions that mimic cellulitis. for patients who are hospitalized, the study also plans to see whether a change in this temperature difference is predictive of response to treatment when compared to the fda standard for early response and patient reported symptoms. this is a pragmatic, prospective cohort study. patients with suspected cellulitis who receive an infectious diseases consult (in the emergency room or urgent clinic) will be approached for consent and enrollment. the goal is to enroll approximately 50 patients with a minimum of 10-15 cases of non-cellulitis. these measurements will not be made available to the treating teams. this is an observational study only comparing the potential value of these measurements to usual clinical care.


Eligibility criteria:
inclusion criteria: * age 18 years or older; * english or french-speaking; * received an infectious diseases consultation to evaluate proven or suspected cellulitis of the upper or lower extremity, either unilaterally or bilaterally; * either no empiric antimicrobials received or, at most, antimicrobials begun within 24 hours of notification for enrollment. exclusion criteria: * presumptive diagnosis of a soft tissue infection of the trunk, head or neck that does not also involve a limb; * patients with only one limb; * patients with significant neuropathies or autonomic syndromes that might affect thermoregulation, such as severe diabetic neuropathy or diabetic dysautonomia, neurologic neoplasms and known vitamin deficiencies; * soft tissue infections requiring definitive surgical source control, such as abscesses or necrotizing fasciitis. * septic arthritis

Keywords: cellulitis temperature venous stasis lymphedema
sensorimotor stimulation on oral feeding

Conditions: Neonates Post Hypoxic Ischemic Encephalopathy

Summary: background: perinatal asphyxia and the resulting hypoxic-ischemic encephalopathy (hie) are significant causes of irreversible adverse neurodevelopmental outcomes in children. neonates and infants with hie commonly experience difficulties in learning the oromotor skills of sucking, swallowing, and breathing. these feeding problems can lead to severe complications such as weight loss, dehydration, malnutrition, and developmental deficits. objective: the study aims to assess the efficacy of sensorimotor stimulation intervention on oral skills in neonates with post-hypoxic ischemic encephalopathy in the neonatal intensive care unit (nicu). methods: the study will include thirty infants with hypoxic-ischemic encephalopathy. they will be divided into two equal groups: the study group receive traditional medical treatment as well as a sensorimotor stimulation program, whereas the control group receive only traditional medical treatment


Eligibility criteria:
inclusion criteria: * neonates, diagnosed with post-hypoxic ischemic encephalopathy exclusion criteria: * neonates with congenital anomalies affecting the oral-facial area, * or syndromes associated with developmental delays, * chronic medical complications

Keywords: neonates hypoxic ischemic encephalopathy sensorimotor stimulation
jump prevalence of sarcopenia and chemobrain in post-cancer patients

Conditions: Cancer; Sarcopenia

Summary: therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. one of the major challenges is the detection and management of treatment side effects for all patients. in addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. after the evaluation day, patients are referred to the most appropriate structures (adapted physical activity, sports for health, and rehabilitation at henry gabriel hospital). jump research is part of axis 2 of the 2021-2030 cancer plan: "limiting sequelae and improving quality of life", through sheets 1 (research) / 6 (access and quality) / 7 (prevention). this leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, adapted physical activity (apa) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers. this study is non-interventional, it uses research on data that is already collected as part of conventional care, during the jump evaluation day. this study allows the investigators to constitute a cohort of patients to study different parameters related to the disease or to the treatments received. our main objective in this study is to describe the muscular and neurocognitive impairment of post-cancer patients evaluated as part of the jump program.


Eligibility criteria:
inclusion criteria: * age : 18 to 74 years * localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy * patient who benefited from the post-cancer assessment day- exclusion criteria: * under 18years * over 74 years * patient who did not received any chemical treatment * patient who do not wish to participate

Keywords: post cancer chemobrain sarcopenia medical evaluation
a phase 1/2 study of incb001158 in combination with chemotherapy in subjects with solid tumors

Conditions: Biliary Tract Cancer (BTC); Colorectal Cancer (CRC); Endometrial Cancer; Gastroesophageal Cancer (GC); Ovarian Cancer; Solid Tumors

Summary: the purpose of this open-label nonrandomized phase 1/2 study is to evaluate incb001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors. * presence of measurable disease per recist v1.1. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * baseline archival tumor specimen available or willingness to undergo a pretreatment tumor biopsy to obtain the specimen. * resolution of treatment-related toxicities. * adequate hepatic, renal, cardiac, and hematologic function. * additional cohort-specific criteria may apply. exclusion criteria: * subjects who participated in any other study in which receipt of an investigational study drug or device occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose. * has received a prior monoclonal antibody within 4 weeks or 5 half-lives (whichever is shorter) before administration of study drug. * has had prior chemotherapy or targeted small molecule therapy within 2 weeks before administration of study treatment. * has received prior approved radiotherapy within 14 days of study therapy. * has had known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry. * has an active autoimmune disease that has required systemic treatment in past 2 years. * has an active infection requiring systemic therapy. * has known active cns metastases and/or carcinomatous meningitis. * women who are pregnant or breastfeeding.

Keywords: incb001158 arginase inhibitor oxaliplatin leucovorin 5 fluorouracil gemcitabine cisplatin paclitaxel solid tumors colorectal cancer biliary tract cancer gastroesophageal cancer endometrial cancer ovarian cancer